Last reviewed · How we verify
A 24-month, Randomized-control, Double-blind, Multi-center, Delayed-start, Pilot Study Evaluating Thrombin Inhibitions Alzheimer's Disease Using 150mg Dabigatran Daily: A Novel Therapeutic Target for Alzheimer's Disease
A randomized-control, double-blind, multi-center, delayed-start, pilot trial evaluating the disease modifying effects of a 150mg once-a-day dose vs. placebo of dabigatran in men and women, between the ages of 50-85 years, confirmed with MCI probably due to AD and mild Alzheimer's Disease.
Details
| Lead sponsor | University of Rhode Island |
|---|---|
| Phase | Phase 1 |
| Status | WITHDRAWN |
| Start date | 2019-05 |
| Completion | 2022-05 |
Conditions
- Mild Cognitive Impairment
- Mild Alzheimer's Disease
Interventions
- Dabigatran
- Placebo - Cap
Primary outcomes
- Evaluate dabigatran efficacy in MCI and mild AD population using changes in targeted plasma and CSF biomarker levels at 9 and 21 months — 9 and 21-months
Evaluate effectiveness of dabigatran (150mg daily) on disease modification measured by changes in targeted plasma and CSF biomarkers associated with the early stages of Alzheimer's disease